3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Vomiting
27
Nausea
20
Neoplasms
8
Breast Neoplasms
6
Lymphoma
3
Stomach Neoplasms
2
Rectal Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Leukemia
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Breast Neoplasms, Male
2
Weight Loss
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Sarcoma
1
Pancreatic Neoplasms
1
Pain
1
Neoplasms, Germ Cell and Embryonal
1
Multiple Myeloma
1
Melanoma
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Inflammatory Breast Neoplasms
1
Hematologic Diseases
1
Glioma
1
Genital Neoplasms, Female
1
Gastrointestinal Neoplasms
1
Interventions
Sunitinib
4
Cyclophosphamide
4
Capecitabine
4
Bevacizumab
4
pazopanib
3
Topotecan
3
Paclitaxel
3
Docetaxel
3
Carboplatin
3
temsirolimus
2
liposomal doxorubicin
2
fludarabine
2
Sorafenib
2
Panobinostat
2
NVP-BKM120
2
Lapatinib
2
Irinotecan
2
Immune Checkpoint Inhibitors
2
Gemcitabine
2
Everolimus
2
Erlotinib Hydrochloride
2
Doxorubicin
2
Bortezomib
2
vadimezan
1
spartalizumab
1
somatostatin receptor 2
1
selinexor
1
selicrelumab
1
perifosine
1
pegylated granulocyte colony-stimulating factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Solid Tumors
×
Palonosetron
×
Clear all
NCT02135510
2020-03-31
MEDEA
Amsterdam UMC, location VUmc
Phase 3
Completed
249 enrolled